FDA Approves Unknown Drug — ADAPTIS
On April 19, 2022, ADAPTIS received FDA approval for ANDA213796, granting the company rights to manufacture a generic version of an undisclosed substance. The green light is expected to bolster ADAPTIS’s product portfolio by enabling the rapid capture of market share in the corresponding therapeutic segment.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed